Hepatocellular carcinoma
Conditions
Interventions
experimental group:Lenvatinib
control group:Blank
Sponsors
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. creatinine clearance> 40 mL / min 3. Child A: Total bilirubin = 28 g / L, AST, ALT, ALP = 1.5 X 10 ^ 9 / L, Hb> = 8.5g / L, PLT> = 75 X 10 ^ 9 / L 5. Blood coagulation function: INR 3 2) Maximum tumor diameter> 8cm 3) Unclear tumor boundary without complete envelope, (2) With gross portal vein, hepatic vein, or bile duct cancer thrombus; (3) Preoperative liver cancer rupture or liver cancer invasion of adjacent organs; 9. Understand and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with other malignancies; 3. Patients with mental illness; 4. Patients who participated in other clinical trials in the past three months; 5. Serious illness with non-malignant tumors can affect patient compliance or put patients at risk; 6. Patients treated with other targeted drugs, immunotherapy such as PD1 antibodies, FOLFOX systemic chemotherapy, Huaier granules after surgery; 7. Urine routine tips> 1 + proteinuria patients will receive a 24-hour urinary protein test, while patients with a 24-hour urine protein> = 1g will not qualify; 8. Have a history of sorafenib and lenvatinib before surgery; 9. Child scored B-C; 10. Patients with other tumor treatments such as radiotherapy and chemotherapy before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival, DFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival, OS;Adverse reactions and safety;time to recurrence, TTR; | — |
Countries
China
Contacts
Public ContactXiao Zhiyu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Outcome results
None listed